{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:03:12Z","timestamp":1790355792260,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005761","name":"Sahlgrenska Academy","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005761","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012538","name":"Swedish Cancer Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012538","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001728","name":"STINT","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001728","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["348-2014-3071"],"award-info":[{"award-number":["348-2014-3071"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011898","name":"Marianne and Marcus Wallenberg Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011898","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Swedish Strategic Research Foundatio\u0144s Infection Biology Program"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.vaccine.2018.07.073","type":"journal-article","created":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T10:12:29Z","timestamp":1534241549000},"page":"6223-6230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Preclinical immunogenicity and protective efficacy of an oral Helicobacter pylori inactivated whole cell vaccine and multiple mutant cholera toxin: A novel and non-toxic mucosal adjuvant"],"prefix":"10.1016","volume":"36","author":[{"given":"Jan","family":"Holmgren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Nordqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareta","family":"Blomquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frida","family":"Jeverstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lebens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukanya","family":"Raghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.vaccine.2018.07.073_b0005","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1086\/657085","article-title":"Immune responses to helicobacter pylori infection in bangladeshi children during their first two years of life and the association between maternal antibodies and onset of infection","volume":"202","author":"Bhuiyan","year":"2010","journal-title":"J Inf Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2018.07.073_b0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1523-5378.2009.00692.x","article-title":"Presence of high numbers of transcriptionally active helicobacter pylori in vomitus from bangladeshi patients suffering from acute gastroenteritis","volume":"14","author":"Janzon","year":"2009","journal-title":"Helicobacter"},{"key":"10.1016\/j.vaccine.2018.07.073_b0015","series-title":"Mucosal Immunology","first-page":"985","article-title":"Chapter 51 - Helicobacter pylori Infection of the Gastric Mucosa","author":"Raghavan","year":"2015"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.073_b0020","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1128\/IAI.73.1.523-531.2005","article-title":"Mucosal FOXP3-expressing CD4+ CD25high regulatory T cells in helicobacter pylori-infected patients","volume":"73","author":"Lundgren","year":"2005","journal-title":"Inf Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2018.07.073_b0025","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gut.2007.137539","article-title":"Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses","volume":"57","author":"Robinson","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.vaccine.2018.07.073_b0030","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.micro.54.1.615","article-title":"The disease spectrum of helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer","volume":"54","author":"Ernst","year":"2000","journal-title":"Annu Rev Microbio"},{"issue":"2","key":"10.1016\/j.vaccine.2018.07.073_b0035","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1128\/IAI.00756-10","article-title":"Proinflammatory cytokine gene expression in the stomach correlates with vaccine-induced protection against Helicobacter pylori infection in mice: an important role for interleukin-17 during the effector phase","volume":"79","author":"Flach","year":"2011","journal-title":"Inf Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2018.07.073_b0040","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1128\/IAI.00536-10","article-title":"Sublingual immunization protects against helicobacter pylori infection and induces T and B cell responses in the stomach","volume":"78","author":"Raghavan","year":"2010","journal-title":"Inf Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2018.07.073_b0045","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1128\/IAI.01407-12","article-title":"A double mutant heat-labile toxin from Escherichia coli, LT(R192G\/L211A), is an effective mucosal adjuvant for vaccination against helicobacter pylori infection","volume":"81","author":"Sjokvist Ottsjo","year":"2013","journal-title":"Inf Immun"},{"issue":"7","key":"10.1016\/j.vaccine.2018.07.073_b0050","doi-asserted-by":"crossref","first-page":"e0131444","DOI":"10.1371\/journal.pone.0131444","article-title":"Defining the roles of IFN-gamma and IL-17A in inflammation and protection against helicobacter pylori infection","volume":"10","author":"Sjokvist Ottsjo","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2018.07.073_b0055","series-title":"Helicobacter pylori Research: From Bench to Bedside","first-page":"575","article-title":"Vaccination against Helicobacter pylori infection","author":"Raghavan","year":"2016"},{"issue":"3","key":"10.1016\/j.vaccine.2018.07.073_b0060","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.coi.2012.03.014","article-title":"Vaccines against mucosal infections","volume":"24","author":"Holmgren","year":"2012","journal-title":"Curr Opin Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2018.07.073_b0065","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.vaccine.2010.11.088","article-title":"A truncated form of HpaA is a promising antigen for use in a vaccine against helicobacter pylori","volume":"29","author":"Flach","year":"2011","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.vaccine.2018.07.073_b0070","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1016\/j.vaccine.2014.10.069","article-title":"Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study","volume":"32","author":"Lundgren","year":"2014","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2018.07.073_b0075","doi-asserted-by":"crossref","first-page":"e51718","DOI":"10.1371\/journal.pone.0051718","article-title":"The adjuvant double mutant escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens","volume":"7","author":"Leach","year":"2012","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.vaccine.2018.07.073_b0080","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1128\/IAI.70.8.4621-4627.2002","article-title":"Effects of oral vaccination and immunomodulation by cholera toxin on experimental helicobacter pylori infection, reinfection, and gastritis","volume":"70","author":"Raghavan","year":"2002","journal-title":"Inf Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2018.07.073_b0085","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0923-2494(97)80867-X","article-title":"\u201cPERFEXT\u201d: a direct method for quantitative assessment of cytokine production in vivo at the local level","volume":"148","author":"Villavedra","year":"1997","journal-title":"Res Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2018.07.073_b0090","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.micinf.2005.07.010","article-title":"Mucosal immune responses are related to reduction of bacterial colonization in the stomach after therapeutic helicobacter pylori immunization in mice","volume":"8","author":"Nystrom","year":"2006","journal-title":"Microbes infect\/Institut Pasteur"},{"key":"10.1016\/j.vaccine.2018.07.073_b0095","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.01407-12","article-title":"The double mutant heat-labile toxin from Escherichia coli, LT (R192G\/L211A) is an effective mucosal adjuvant for vaccination against helicobacter pylori infection","author":"Sjokvist Ottsjo","year":"2013","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2018.07.073_b0100","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.vaccine.2009.10.147","article-title":"Toward the development of a stable, freeze-dried formulation of helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin","volume":"28","author":"Summerton","year":"2010","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.073_b0105","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1128\/IAI.67.1.337-341.1999","article-title":"Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions","volume":"67","author":"Pappo","year":"1999","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2018.07.073_b0110","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1586\/egh.11.44","article-title":"Regulatory T cells in gastrointestinal tumors","volume":"5","author":"Raghavan","year":"2011","journal-title":"Expert Rev Gastro Hepat"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.073_b0115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/187153012799278974","article-title":"Immune modulation by regulatory T cells in helicobacter pylori-associated diseases","volume":"12","author":"Raghavan","year":"2012","journal-title":"Endocrine Metab Immune Disorders Drug Targets"},{"issue":"4","key":"10.1016\/j.vaccine.2018.07.073_b0120","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1128\/CVI.00538-10","article-title":"Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G\/L211A), as a safe and effective oral adjuvant","volume":"18","author":"Norton","year":"2011","journal-title":"Clin Vaccine Immun: CVI"},{"issue":"18","key":"10.1016\/j.vaccine.2018.07.073_b0125","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.vaccine.2016.03.002","article-title":"Construction and preclinical evaluation of mmCT, a novel mutant cholera toxin adjuvant that can be efficiently produced in genetically manipulated vibrio cholerae","volume":"34","author":"Lebens","year":"2016","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2018.07.073_b0130","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1128\/IAI.00181-12","article-title":"The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens","volume":"80","author":"Norton","year":"2012","journal-title":"Infect Immun"},{"issue":"20","key":"10.1016\/j.vaccine.2018.07.073_b0135","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/j.vaccine.2013.03.027","volume":"31","author":"Holmgren","year":"2013","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2018.07.073_b0140","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1128\/IAI.69.6.3581-3590.2001","article-title":"Safety and immunogenicity of oral inactivated whole-cell helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection","volume":"69","author":"Kotloff","year":"2001","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.073_b0145","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1053\/j.gastro.2008.09.017","article-title":"Vaccination of mice against H pylori induces a strong Th-17 response and immunity that is neutrophil dependent","volume":"136","author":"DeLyria","year":"2009","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.vaccine.2018.07.073_b0150","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/imm.12676","article-title":"Induction of mucosal immune responses against helicobacter pylori infection after sublingual and intragastric route of immunization","volume":"150","author":"Sjokvist Ottsjo","year":"2017","journal-title":"Immunology"},{"issue":"8","key":"10.1016\/j.vaccine.2018.07.073_b0155","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.4049\/jimmunol.1401633","article-title":"Cholera toxin, and the related nontoxic adjuvants mmCT and dmLT, promote human Th17 responses via cyclic AMP-protein kinase A and inflammasome-dependent IL-1 signaling","volume":"194","author":"Larena","year":"2015","journal-title":"J Immunol."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1831082X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1831082X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:28:28Z","timestamp":1759400908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1831082X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":31,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0264410X1831082X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.073","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical immunogenicity and protective efficacy of an oral Helicobacter pylori inactivated whole cell vaccine and multiple mutant cholera toxin: A novel and non-toxic mucosal adjuvant","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}